Merck Halts Development of Osteoporosis Drug Due to Stroke Risk

  • The company won’t file for regulatory approval of odanacatib
  • Findings will be presented at Bone Mineral Research meeting

Merck & Co. will halt development of an experimental drug to treat osteoporosis called odanacatib after a key study showed that older women taking it were more likely to suffer a stroke.

The risk was confirmed by an independent analysis of results from the final study needed to get a new drug approved, the Kenilworth, New Jersey-based company said Friday in a statement. Merck won’t pursue regulatory approval of the bone-strengthening medicine.

Merck, which originally planned to file for approval in 2013, faced delays as it conducted a second study to verify its safety and effectiveness. A first trial had been stopped early the previous year because the medicine worked so well, significantly reducing the risk of fractures in post-menopausal women. Analysts anticipated the drug would have reached about $230 million in sales in 2020, based on six estimates compiled by Bloomberg, a fraction of Merck’s annual revenue.

The shares rose 0.1 percent to $63.16 at 10:08 a.m. in New York. The full findings on the stroke risk will be presented at the American Society for Bone Mineral Research meeting in September.

    Before it's here, it's on the Bloomberg Terminal.